


Modern JAK Inhibitor Strategies in Individualized Myelofibrosis Management:

Insights From Community Oncologists Following Participation in Collaborative Learning Workshops

First-line Therapy Selection With JAK Inhibitors

Healthcare professionals are adopting **more personalized** approaches to initial therapy selection.

Although many healthcare professionals prefer ruxolitinib as the first-line option for patients in whom JAK inhibitors are indicated, they are **increasingly considering newer JAK inhibitors** based on specific patient characteristics.



“

We had one drug; now we have multiple. So now you try to figure out which drug is better for which patients . . . if platelets are too low, then pacritinib. And if they're too anemic, then now momelotinib.

”

Second-line Therapy Selection

Physicians reported **increased confidence** in selecting second-line therapy based on specific patient factors.

For patients with intolerance, or suboptimal response or progression on first-line JAK inhibitors, switching to a different JAK inhibitor or enrolling in clinical trials can be considered.

Momelotinib

Considered for patients with prominent anemia



Pacritinib

Emerging as preferred option for patients with thrombocytopenia



Fedratinib

Viewed as an option for patients without significant cytopenias

Proactive Toxicity Management

Reported strategies include early intervention with antiemetics, antidiarrheals; dose modifications to maintain therapeutic benefit; supportive care measures; and multimodal assessment (eg, evaluation of symptom burden, blood count trends, spleen size assessment, patient-reported outcomes).



Prophylactic management



Dose modification



Supportive care

Patient Education

Participants emphasized the importance of proactively educating patients on treatment-related toxicities and discussing the potential for treatment failure from therapy initiation.



Provide written materials



Set adverse effect expectations



Counsel patients

Workshop Impact on Clinical Confidence

Participants reported increased confidence in:

- Comparing and selecting JAK inhibitors
- Managing treatment-related toxicities
- Identifying and addressing treatment failure
- Implementing personalized treatment approaches



I do think these [workshops] do help a lot. Hearing the collective experience helps you incorporate what other people are doing in your practice.



Practical guidance on symptom and toxicity management

Updates on emerging therapeutic approaches

Future Directions and Needs

Long-term efficacy and safety data for newer agents

Opportunities for peer collaboration and expert consultation



powered by CEA